The European Medicines Agency's safety committee has initiated a regulatory review of injectable iron medicines after receiving reports that link these treatments to low blood phosphate levels and bone complications, including bone softening.
These injectable formulations are used to treat iron deficiency and iron-deficiency anemia in situations where oral iron preparations do not achieve sufficient results, cannot be used, or when there is a clinical need to restore iron levels quickly, the EMA committee said.
Concerns prompting the review center on reports about whether current measures to mitigate the risk of low phosphate are effective for products that contain the active substance ferric carboxymaltose. Among the reports were serious instances of low blood phosphate and bone softening occurring in patients who had received only one or two doses of the active substance, according to the regulator.
As part of the review, the safety committee will examine whether the newly reported adverse events change the overall risk-benefit profile of injectable iron medicines. The committee will also consider whether modifications to existing marketing authorizations are warranted based on its assessment.
The EMA said its review has been broadened to cover all injectable iron-containing medicines after similar cases were reported with products beyond those containing ferric carboxymaltose. This expansion reflects the regulator's aim to determine if the issue is limited to a single active substance or pertains to injectable iron therapies more widely.
Regulatory action in other jurisdictions has been reported this week as well. The U.S. Food and Drug Administration added a boxed warning to the labels of ferric carboxymaltose injections to highlight the risk of low phosphate levels, a measure intended to alert clinicians and patients to the potential adverse effect.
The EMA safety committee's forthcoming evaluation will focus on whether reported incidents alter the medicines' established balance of benefits and risks and whether safety information or marketing conditions need revision. The regulator's review process will determine what, if any, regulatory changes are appropriate for injectable iron therapies across markets covered by the EMA.
Context limitations
The reporting and statements cited by the EMA mention specific adverse events and regulatory responses but do not provide further clinical or numerical details about the cases. The regulator's review is ongoing, and outcomes or regulatory decisions have not been announced yet.